Biora-tm_rgb.jpg
Biora Therapeutics Announces Positive Clinical Trial Results for BT-600
July 01, 2024 08:00 ET | Biora Therapeutics, Inc.
BT-600 was well tolerated and met all trial objectives, demonstrating the NaviCap platform’s ability to deliver therapeutics directly to the colon
Noah_Medical_logo_MASTER.jpg
Journal of Respirology Publishes Clinical Trial Data Demonstrating the Benefits of Noah Medical’s Galaxy System
June 27, 2024 14:39 ET | Noah Medical
FRONTIER Study demonstrates Noah Medical's Galaxy System’s use of proprietary TiLT+ Technology to successfully navigate peripheral pulmonary nodules
60Degrees_logo_RGB_Logo.jpg
First Patient Enrolled in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis at Tufts Medical Center; First and Only Study of Its Kind
June 27, 2024 07:59 ET | Sixty Degrees Pharmaceuticals
60 Degrees Pharmaceuticals enrolls first patient in a clinical study at Tufts to assess safety and efficacy of tafenoquine in treating acute babesiosis.
Y-Prime, LLC 2024
YPrime Research Reveals User-Centric eCOA Technologies as Key to Overcoming Challenges in Endocrinology Clinical Trials
June 25, 2024 08:00 ET | Y-Prime, LLC
New YPrime research report sheds light on how technology can help solve challenges in endocrinology clinical trials.
BioNTech und Duality
BioNTech und DualityBio erhalten Fast-Track-Status der FDA für Antikörper-Wirkstoff-Konjugat-Kandidat BNT324/DB-1311 bei Prostatakrebs
June 24, 2024 06:45 ET | BioNTech SE
Der Status basiert auf präklinischen Daten und Daten aus einer laufenden Phase-1/2-Studie für BNT324/DB-1311; vorläufige klinische Phase-1/2-Daten zeigten eine Anti-Tumor-Aktivität und ein...
BioNTech and Duality
BioNTech and DualityBio Receive FDA Fast Track Designation for Antibody-Drug Conjugate Candidate BNT324/DB-1311 in Prostate Cancer
June 24, 2024 06:45 ET | BioNTech SE
Designation is based on pre-clinical data and data from an ongoing Phase 1/2 trial for BNT324/DB-1311, with antitumor activity and a manageable safety profile demonstrated by preliminary Phase 1/2...
Poltreg_logo_kolor.jpg
PolTREG’s type-1 diabetes Treg cell therapy PTG-007 demonstrates long-term safety and efficacy for up to 12 years
June 24, 2024 01:30 ET | PolTREG S.A.
                 PTG-007 administration resulted in improved remission and insulin secretion Patients monitored for up to 12 yearsPlanned pivotal Phase 2/3 study is final step for PolTREG to...
astrivax_high resolution.png
AstriVax enters clinical phase with its novel vaccine platform technology
June 24, 2024 01:00 ET | AstriVax
The first participants have been dosed in SAFYR, a Phase I clinical trial to test the safety and efficacy of two prophylactic vaccines developed with AstriVax technology.  The study will also provide...
NMD_Logo3_reg.jpg
NMD Pharma Receives IND Clearance from the FDA to initiate a Phase 2 Clinical Trial of NMD670 in Charcot-Marie-Tooth disease in the US
June 18, 2024 07:00 ET | NMD Pharma
NMD Pharma Receives IND Clearance from the FDA to initiate a Phase 2 Clinical Trial of NMD670 in Charcot-Marie-Tooth disease in the US Aarhus, Denmark, 18 June 2024 – NMD Pharma A/S, a clinical-stage...
NMD_Logo3_reg.jpg
NMD Pharma Receives IND Clearance from the FDA to initiate a Phase 2 Clinical Trial of NMD670 in Charcot-Marie-Tooth disease in the US
June 18, 2024 01:00 ET | NMD Pharma
NMD Pharma Receives IND Clearance from the FDA to initiate a Phase 2 Clinical Trial of NMD670 in Charcot-Marie-Tooth disease in the US Aarhus, Denmark, 18 June 2024 – NMD Pharma A/S, a clinical-stage...